These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Therapy of Parkinson's disease: are we at the end of the road? Nag D J Assoc Physicians India; 1992 Jun; 40(6):361-3. PubMed ID: 1360470 [No Abstract] [Full Text] [Related]
11. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Fernandez HH; Chen JJ Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937 [TBL] [Abstract][Full Text] [Related]
12. Treatment of Parkinson's disease. From theory to practice. Ahlskog JE Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048 [TBL] [Abstract][Full Text] [Related]
13. Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263 [TBL] [Abstract][Full Text] [Related]
14. Neurotoxicity and neuroprotection in Parkinson's disease. Lange KW; Youdim MB; Riederer P J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247 [TBL] [Abstract][Full Text] [Related]
15. DATATOP-study: significance of its results in the treatment of Parkinson's disease. Schneider E J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074 [TBL] [Abstract][Full Text] [Related]
16. Deprenyl and levodopa and Parkinson's disease progression. Fowler JS; Fazzini E; Volkow ND Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616 [No Abstract] [Full Text] [Related]